# ONDINE BIOPHARMA Corp: Form D filings

ONDINE BIOPHARMA Corp, a biotechnology company in Vancouver, filed 4 Form D notices with the SEC between 2009 and 2010. The latest, on April 7, 2010, reports $45,463 sold of a $45,463 offering to 3 investors.

Find out what ONDINE BIOPHARMA Corp does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20ONDINE%20BIOPHARMA%20Corp%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=ONDINE%20BIOPHARMA%20Corp&page=%2Fdata%2Fform-d%2Fcompany%2Fondine-biopharma-corp-1286774)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20ONDINE%20BIOPHARMA%20Corp%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=ONDINE%20BIOPHARMA%20Corp&page=%2Fdata%2Fform-d%2Fcompany%2Fondine-biopharma-corp-1286774)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in Biotechnology](https://specstream.ai/data/form-d/industry/biotechnology): 1,568 rows, by operating companies, filed since November 1, 2024, $78.40, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/biotechnology
- [Form D filings](https://specstream.ai/data/form-d): 44,302 rows, by operating companies, filed since November 1, 2024, $523.02, or the new rows each week for $92.05 a month. Buy: https://specstream.ai/data/form-d

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 910-1100 MELVILLE ST, Vancouver, V6E4A
- Phone: (604) 669-0555
- Industry: Biotechnology
- Entity type: Corporation
- Incorporated in: British Columbia, Canada
- Revenue range: $1 - $1,000,000
- Exemptions claimed: Rule 506
- SEC identifier (CIK): 1286774

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Apr 7, 2010 | New notice | $45,463 | $45,463 | $0 | 3 | Apr 5, 2010 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1286774/000128677410000001/0001286774-10-000001-index.htm) |
| Dec 29, 2009 | New notice | $239,308 | $239,308 | $0 | 2 | Dec 23, 2009 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1286774/000128677409000007/0001286774-09-000007-index.htm) |
| Dec 21, 2009 | New notice | $480,183 | $480,183 | $0 | 4 | Dec 7, 2009 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1286774/000128677409000006/0001286774-09-000006-index.htm) |
| Sep 11, 2009 | New notice | $43,360 | $43,360 | $0 | 1 | Jun 24, 2009 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1286774/000128677409000005/0001286774-09-000005-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Carolyn Cross | Executive Officer, Director |  |
| Thomas Dawson | Executive Officer |  |
| Colin Watt | Director |  |
| Michael Crane | Director |  |
| Terence Holland | Director |  |
| Margaret Shaw | Director |  |
| Merrill Biel | Director |  |
| Nicholas Loebel | Executive Officer |  |
| William Harper | Executive Officer |  |

[Every Form D from the week of Apr 5, 2010](https://specstream.ai/data/form-d/week/2010-04-05) · [All recent Biotechnology filings](https://specstream.ai/data/form-d/industry/biotechnology)

Read from SEC EDGAR. Amount sold is what ONDINE BIOPHARMA Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).